CL2010001358A1 - Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina. - Google Patents
Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina.Info
- Publication number
- CL2010001358A1 CL2010001358A1 CL2010001358A CL2010001358A CL2010001358A1 CL 2010001358 A1 CL2010001358 A1 CL 2010001358A1 CL 2010001358 A CL2010001358 A CL 2010001358A CL 2010001358 A CL2010001358 A CL 2010001358A CL 2010001358 A1 CL2010001358 A1 CL 2010001358A1
- Authority
- CL
- Chile
- Prior art keywords
- rasagiline
- pramipexole
- less
- combination
- pharmaceutical composition
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 title 2
- 229960003089 pramipexole Drugs 0.000 title 2
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title 2
- 229960000245 rasagiline Drugs 0.000 title 2
- 229940000425 combination drug Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5932608P | 2008-06-06 | 2008-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2010001358A1 true CL2010001358A1 (es) | 2011-08-19 |
Family
ID=41051156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2010001358A CL2010001358A1 (es) | 2008-06-06 | 2010-12-06 | Composicion farmaceutica que comprende un vehiculo farmaceuticamente aceptable y una combinacion de dos dosis de pramipexol y rasagilina, en donde la combinacion a dosis fija contiene desde 0,06 a menos de 1,5 mg de pramipexol y desde 0,05 mg a menos de 1,0 mg de rasagilina. |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8969417B2 (enExample) |
| EP (1) | EP2303330B2 (enExample) |
| JP (1) | JP5648216B2 (enExample) |
| KR (1) | KR101613749B1 (enExample) |
| CN (1) | CN102105169B (enExample) |
| AU (1) | AU2009254730B2 (enExample) |
| BR (1) | BRPI0914902B8 (enExample) |
| CA (1) | CA2726833C (enExample) |
| CL (1) | CL2010001358A1 (enExample) |
| CY (1) | CY1119865T1 (enExample) |
| DK (1) | DK2303330T4 (enExample) |
| ES (1) | ES2659394T5 (enExample) |
| HU (1) | HUE037974T2 (enExample) |
| LT (1) | LT2303330T (enExample) |
| MX (1) | MX2010013393A (enExample) |
| NO (1) | NO2303330T3 (enExample) |
| NZ (1) | NZ590291A (enExample) |
| PL (1) | PL2303330T5 (enExample) |
| PT (1) | PT2303330T (enExample) |
| RU (1) | RU2540470C9 (enExample) |
| WO (1) | WO2009147681A1 (enExample) |
| ZA (1) | ZA201100034B (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9943489B2 (en) | 2010-02-03 | 2018-04-17 | Pharmatwob Ltd. | Extended release formulations of rasagiline and uses thereof |
| TW201304822A (zh) * | 2010-11-15 | 2013-02-01 | Vectura Ltd | 組成物及用途 |
| US9504657B2 (en) * | 2012-01-12 | 2016-11-29 | Pharmatwob Ltd. | Fixed dose combination therapy of Parkinson's disease |
| JP6243351B2 (ja) * | 2012-01-12 | 2017-12-06 | ファーマ ツゥ ビー リミテッド | パーキンソン病の固定投与量薬剤組合せ治療 |
| WO2013168032A1 (en) * | 2012-05-07 | 2013-11-14 | Micro Labs Limited | Pharmaceutical compositions comprising rasagiline |
| KR101320945B1 (ko) * | 2012-07-03 | 2013-10-23 | 주식회사파마킹 | 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제 |
| MX2015003812A (es) * | 2012-09-27 | 2015-07-17 | Teva Pharma | Combinacion de rasagilina y pridopidina para tratar trastornos neurodegenerativos, en particular enfermedad de huntington. |
| BR112015022896B1 (pt) | 2013-03-15 | 2022-08-23 | Chongxi Yu | Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson |
| EP2808023A1 (en) * | 2013-05-30 | 2014-12-03 | Université Pierre et Marie Curie (Paris 6) | New drug for the treatment and/or prevention of depressive disorders |
| CN104473942A (zh) * | 2014-12-12 | 2015-04-01 | 青岛大学 | 一种抗帕金森氏病的药物组合物 |
| CA2986891C (en) | 2015-05-26 | 2022-01-04 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Compositions for use in treating parkinson's disease and related disorders |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| US20170143681A1 (en) * | 2015-11-02 | 2017-05-25 | Apkarian Technologies Llc | Methods and compositions for treating pain |
| EP3558378A4 (en) * | 2016-12-22 | 2020-09-16 | Synnerva Ltd. | LOW DOSE COMBINATION OF MEDICINAL PRODUCTS FOR THE PREVENTION AND TREATMENT OF NEURAL DAMAGE |
| WO2019010491A1 (en) * | 2017-07-07 | 2019-01-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS |
| US20190153102A1 (en) | 2017-09-28 | 2019-05-23 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
| JP6596483B2 (ja) * | 2017-12-28 | 2019-10-23 | テックフィールズ ファーマ カンパニー リミテッド | パ−キンソン病治療用の新規高透過薬物及びその組成物 |
| WO2020084168A1 (en) * | 2018-10-26 | 2020-04-30 | Icm (Institut Du Cerveau Et De La Moelle Épinière) | Tetracycline compound for treating drug-induced dyskinesia |
| CN113924086A (zh) * | 2019-04-17 | 2022-01-11 | 维奇健康科学有限责任公司 | 液体药物组合物 |
| WO2020227646A1 (en) * | 2019-05-09 | 2020-11-12 | Apkarian Technologies Llc | Methods and compositions for treating pain |
| US20230028539A1 (en) | 2019-12-06 | 2023-01-26 | Shanghai Pharmaceuticals Holding Co., Ltd. | Pharmaceutical composition, complementary kit and application thereof |
| AU2021292406B2 (en) | 2020-06-18 | 2024-03-14 | XWPharma Ltd. | Controlled release granulations of water-soluble active pharmaceutical ingredients |
| WO2022020621A1 (en) | 2020-07-24 | 2022-01-27 | XWPharma Ltd. | Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative |
| TW202227131A (zh) * | 2020-09-10 | 2022-07-16 | 愛爾蘭商普羅佘納生物科技有限公司 | 帕金森氏症之治療 |
| AU2021357705B2 (en) | 2020-10-05 | 2024-09-26 | XWPharma Ltd. | Modified release compositions of a gamma-hydroxybutyric acid derivative |
| CN114762684B (zh) * | 2021-01-14 | 2023-11-21 | 华益泰康药业股份有限公司 | 一种治疗帕金森的缓释胶囊及其制备方法 |
| DK4308086T3 (da) | 2021-03-19 | 2025-11-17 | Xwpharma Ltd | Farmakokinetik af formuleringer med kombineret frigivelse af et gamma-hydroxysmørsyrederivat |
| KR102903389B1 (ko) * | 2022-11-30 | 2025-12-23 | 주식회사한국파마 | 신경퇴행성 질환 예방 또는 치료용 필름코팅정제 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0241809B1 (de) * | 1986-04-16 | 1990-08-08 | ASTA Pharma Aktiengesellschaft | Synergistische Kombination von Amantadin und Selegilin |
| US5221536A (en) * | 1990-05-07 | 1993-06-22 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| US5190763A (en) | 1990-05-07 | 1993-03-02 | Alza Corporation | Dosage form indicated for the management of abnormal posture, tremor and involuntary movement |
| DK0828513T3 (da) * | 1995-05-26 | 2004-04-13 | Pfizer | Kombinationspræparater til behandling af parkinsonisme, indeholdende selektive NMDA-antagonister |
| CN1436080A (zh) | 2000-04-19 | 2003-08-13 | 利利艾科斯有限公司 | 环gmp－特异性磷酸二酯酶抑制剂治疗帕金森氏病的用途 |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| FR2857594B1 (fr) * | 2003-07-17 | 2005-09-16 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale de piribedil |
| KR20060124712A (ko) | 2004-02-20 | 2006-12-05 | 노파르티스 아게 | 신경퇴행 및 인지 장애를 치료하기 위한 ｄｐｐ ⅳ 억제제 |
| EP1901721A1 (en) | 2005-06-23 | 2008-03-26 | Spherics, Inc. | Delayed release or extended-delayed release dosage forms of pramipexole |
| US20090325911A1 (en) | 2005-10-21 | 2009-12-31 | Caritas St. Elizabeth Medical Center Of Boston, Inc. | Use of Androgens for the Treatment of Parkinson's Disease |
| EP1970055B1 (en) * | 2005-12-29 | 2010-11-24 | Osmotica Kereskedelmi És Szolgáltató Kft | Multi-layered tablet with triple release combination |
| BRPI0708071A8 (pt) | 2006-02-17 | 2017-12-26 | Birds Pharma Gmbh Berolina Innovative Res & Development Services | Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos |
| AU2007235517B2 (en) | 2006-04-03 | 2013-01-31 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of Restless Legs Syndrome |
| CN102160865A (zh) * | 2006-05-16 | 2011-08-24 | 诺普神经科学股份有限公司 | R(+)和s(-)普拉克索的组合物以及使用该组合物的方法 |
| EP2040698A4 (en) | 2006-07-14 | 2011-08-10 | Shionogi & Co | OXIM CONNECTIONS AND ITS USE |
| TW200820963A (en) | 2006-07-28 | 2008-05-16 | Xenoport Inc | Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use |
| ATE510538T1 (de) | 2006-08-11 | 2011-06-15 | Univ Johns Hopkins | Zusammensetzungen und verfahren für nervenschutz |
| CN101573334A (zh) | 2006-08-21 | 2009-11-04 | 普雷萨药品公司 | 用于治疗中枢神经系统障碍的多介质转运体抑制剂 |
| US7622495B2 (en) | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| ES2389456T3 (es) | 2006-11-01 | 2012-10-26 | Purdue Pharma Lp | Compuestos de fenilpropionamida y uso de los mismos |
| EP2150239A1 (en) † | 2007-04-24 | 2010-02-10 | Boehringer Ingelheim International GmbH | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
-
2009
- 2009-06-07 RU RU2010154716/15A patent/RU2540470C9/ru active
- 2009-06-07 NO NO09758025A patent/NO2303330T3/no unknown
- 2009-06-07 ES ES09758025T patent/ES2659394T5/es active Active
- 2009-06-07 DK DK09758025.2T patent/DK2303330T4/da active
- 2009-06-07 CA CA2726833A patent/CA2726833C/en active Active
- 2009-06-07 PT PT97580252T patent/PT2303330T/pt unknown
- 2009-06-07 KR KR1020117000189A patent/KR101613749B1/ko active Active
- 2009-06-07 HU HUE09758025A patent/HUE037974T2/hu unknown
- 2009-06-07 MX MX2010013393A patent/MX2010013393A/es active IP Right Grant
- 2009-06-07 JP JP2011512269A patent/JP5648216B2/ja active Active
- 2009-06-07 EP EP09758025.2A patent/EP2303330B2/en active Active
- 2009-06-07 CN CN200980129250.2A patent/CN102105169B/zh active Active
- 2009-06-07 WO PCT/IL2009/000567 patent/WO2009147681A1/en not_active Ceased
- 2009-06-07 NZ NZ590291A patent/NZ590291A/xx not_active IP Right Cessation
- 2009-06-07 AU AU2009254730A patent/AU2009254730B2/en active Active
- 2009-06-07 US US12/996,455 patent/US8969417B2/en active Active
- 2009-06-07 PL PL09758025T patent/PL2303330T5/pl unknown
- 2009-06-07 LT LTEP09758025.2T patent/LT2303330T/lt unknown
- 2009-06-07 BR BRPI0914902A patent/BRPI0914902B8/pt active IP Right Grant
-
2010
- 2010-12-06 CL CL2010001358A patent/CL2010001358A1/es unknown
-
2011
- 2011-01-03 ZA ZA2011/00034A patent/ZA201100034B/en unknown
-
2015
- 2015-01-22 US US14/602,518 patent/US9259418B2/en active Active - Reinstated
-
2018
- 2018-01-31 CY CY20181100112T patent/CY1119865T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| BR0312573A (pt) | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina | |
| UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
| ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| ECSP066807A (es) | Formulaciones galénicas de compuestos orgánicos | |
| CU20070203A7 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
| MX2019007956A (es) | Liberacion autorregulada de ingrediente farmaceutico activo. | |
| CR11724A (es) | Agente para tratar enfermedades | |
| CO6251236A2 (es) | Composiciones terapeuticas que comprenden acido 6-(3-cloro-2-fluorobencil)-1´-[(25)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolin-3-carboxilico | |
| GT201000095A (es) | Producto de dispersión sólida que contiene un compuesto a base de n-aril urea | |
| AR090885A1 (es) | Uso de laquinimod en alta dosis para el tratamiento de la esclerosis multiple | |
| AR077125A1 (es) | Combinaciones farmaceuticas utiles para tratar el vhc | |
| CO6341624A2 (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| ES2570401T3 (es) | Métodos de tratamiento usando dosis únicas de oritavancina | |
| CO2024002748A2 (es) | Profármaco de derivados de pirrolidona como activador de glucocinasa | |
| DK2802319T3 (da) | Fastdosiskombinationsterapi for parkinsons sygdom | |
| CR8603A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
| RU2011148355A (ru) | Применение аллопуринола для ладонно-родошвенного синдрома | |
| AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
| AR085132A1 (es) | Composiciones farmaceuticas para el tratamiento de glioma maligno | |
| AR065139A1 (es) | Medicamento para el tratamiento de la endometriosis | |
| UA100883C2 (ru) | Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона | |
| AR075866A1 (es) | Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica. |